Bioventus Inc. (NASDAQ: BVS) reported Q3 EPS of $0.05, $0.07 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $120.8 million versus the consensus estimate of $119 million.

2023 Financial Guidance:

For the twelve months ending December 31, 2023, the Company now expects:

Net sales of $498 million to $505 million, versus the consensus of $499.8 million
Adjusted EBITDA* of $84 million to $87 million
Non-GAAP EPS* of ($0.12) to ($0.09), versus the consenus of ($0.42)

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.